SCHEMBL18323130

SCHEMBL18323130

CSc1cc(C(=O)Nc2cc(Br)c(S(N)(=O)=O)cn2)cs1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.36
▸ RAB9A P51151 6/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ TP53 P04637 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ MTOR P42345 1/20 0.35
▸ F10 P00742 4/20 0.35
▸ KLK1 P06870 1/20 0.35
▸ PIK3C3 Q8NEB9 2/20 0.34
▸ MAP3K5 Q99683 2/20 0.34
▸ KMT2A Q03164 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ CA12 O43570 1/20 0.32
▸ CA9 Q16790 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18323205 0.76 NPC1 (0.32) NPC1RAB9ASMN1; SMN2TP53NPSR1
SCHEMBL18323199 0.75 ROR1 (0.33) NPC1RAB9ASMN1; SMN2TP53NPSR1
SCHEMBL18323129 0.75 F10 (0.45) NPC1RAB9ASMN1; SMN2MTORF10
SCHEMBL18323128 0.74 NPC1 (0.52) NPC1RAB9ASMN1; SMN2MTORF10
SCHEMBL18323127 0.67 MAP3K5 (0.39) NPC1RAB9ATP53F10KLK1
SCHEMBL18323132 0.62 KMT2A (0.32) KMT2A
SCHEMBL15907221 0.60 MTOR (0.56) NPC1RAB9ASMN1; SMN2TP53MTOR
SCHEMBL18323503 0.59 ALDH1A1 (0.49) NPC1RAB9ASMN1; SMN2TP53NPSR1
SCHEMBL18323294 0.59 NPC1 (0.49) NPC1RAB9ASMN1; SMN2NPSR1L3MBTL1
SCHEMBL15907219 0.56 MTOR (0.57) NPC1RAB9ASMN1; SMN2TP53MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 — — US disclosed
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 — — US disclosed
Send feedback